Literature DB >> 27122755

Outpatient Hypertension Control and Prescribing Habits for Hypertension in Taiwan.

Chung-Sheng Lin1, Yung-Hua Chu2, Yi-Jen Hung3, Du-Yi Lee4, Cheng-Yun Chen5.   

Abstract

BACKGROUND: Hypertension control is of the utmost importance for reducing cardiovascular risk. In Taiwan, the hypertension control rate of the general population is low (25%). We investigated the factors affecting outpatient hypertension control to determine whether the low control rate stems from clinician unawareness or inadequate public education.
METHODS: Hypertensive patients were recruited between 2003 and 2004 by 13 cardiologists and 9 non-cardiologists from 19 hospitals distributed across four geographical areas of Taiwan. Each clinician recruited 100 consecutive patients from outpatient clinics and reported their drug prescriptions, co-morbidities, and blood pressure (BP) levels. Data were analyzed using the chi square test and multivariate logistic regression analyses.
RESULTS: Of the 2145 enrolled patients, 63% attained the BP goal of < 140/90 mmHg. BP control rates were higher in older patients, and in patients who were treated by cardiologists and at medical centers. The control rate of high risk co-morbidity patients (BP goal of < 130/80 mmHg) was 36%, which was significantly lower than the 62% control rate of low risk patients (BP goal of < 140/90 mmHg). Cardiologists achieved higher BP control rates (65% vs. 60%; p = 0.0039), and prescribed more combination regimens (p < 0.0001) and beta blockers than non-cardiologists. Overall, 63% of patients received combination therapy. Calcium channel blockers were the most commonly prescribed antihypertensive drugs, followed by beta blockers, angiotensin receptor blockers, diuretics, and angiotensin-converting enzyme inhibitors.
CONCLUSIONS: Two-thirds of the entire study population received combination therapy, although BP control rate is still less than optimal in the high risk patients. Ultimately, a more aggressive strategy is strongly encouraged for patients considered to be at high risk. KEY WORDS: Combination therapy; Hypertension control rate; Prescribing habit.

Entities:  

Year:  2013        PMID: 27122755      PMCID: PMC4805033     

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  27 in total

1.  Cardiovascular protection and blood pressure reduction: a meta-analysis.

Authors:  J A Staessen; J G Wang; L Thijs
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

2.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

3.  Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan.

Authors:  Chung-Sheng Lin; Wen-Ling Lee; Yi-Jen Hung; Du-Yi Lee; Kuei-Feng Chen; Wen-Che Chi; Shin-Chieh Chang
Journal:  Int J Cardiol       Date:  2010-11-20       Impact factor: 4.164

4.  Coordinating care--a perilous journey through the health care system.

Authors:  Thomas Bodenheimer
Journal:  N Engl J Med       Date:  2008-03-06       Impact factor: 91.245

5.  The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment.

Authors:  S H Cheng; T L Chiang
Journal:  JAMA       Date:  1997-07-09       Impact factor: 56.272

6.  Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice.

Authors:  Giovanni Corrao; Federica Nicotra; Andrea Parodi; Antonella Zambon; Franca Heiman; Luca Merlino; Ida Fortino; Giancarlo Cesana; Giuseppe Mancia
Journal:  Hypertension       Date:  2011-08-08       Impact factor: 10.190

7.  ABC control of diabetes: survey data from National Diabetes Health Promotion Centers in Taiwan.

Authors:  Neng-Chun Yu; Hsiu-Yueh Su; Shih-Tzer Tsai; Boniface J Lin; Ruei-Shiang Shiu; Yu-Chuan Hsieh; Wayne Huey-Herng Sheu
Journal:  Diabetes Res Clin Pract       Date:  2009-03-26       Impact factor: 5.602

Review 8.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

9.  Evidence for improved control of hypertension in Taiwan: 1993-2002.

Authors:  Ta-Chen Su; Chyi-Huey Bai; Hsing-Yi Chang; San-Lin You; Kuo-Liong Chien; Ming-Fong Chen; Hsin-Jen Chen; Wen-Harn Pan; Chin-Hsiao Tseng; Shou-Hsia Cheng; Baai-Shyun Hurng; Lee-Ching Hwang; Chien-Jen Chen
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

10.  Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan.

Authors:  Pang-Hsiang Liu; Jung-Der Wang
Journal:  BMC Health Serv Res       Date:  2008-06-18       Impact factor: 2.655

View more
  3 in total

Review 1.  Mini-Review of the Chin-Shan Community Cardiovascular Cohort Study in Population Health Research in Taiwan.

Authors:  Kuo-Liong Chien
Journal:  Acta Cardiol Sin       Date:  2017-05       Impact factor: 2.672

2.  An Integrated Community-Based Blood Pressure Telemonitoring Program - A Population-Based Observational Study.

Authors:  Ju-Yeh Yang; Yen-Wen Wu; Wenpo Chuang; Tzu-Chun Lin; Shu-Wen Chang; Shou-Hsia Cheng; Raymond N Kuo
Journal:  Acta Cardiol Sin       Date:  2022-09       Impact factor: 1.800

3.  Relationships Between Bronchodilators, Steroids, Antiarrhythmic Drugs, Antidepressants, and Benzodiazepines and Heart Disease and Ischemic Stroke in Patients With Predominant Bronchiectasis and Asthma.

Authors:  Jun-Jun Yeh; Mei-Chu Lai; Yu-Cih Yang; Chung-Y Hsu; Chia-Hung Kao
Journal:  Front Cardiovasc Med       Date:  2022-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.